Serotonin 5-HT6 receptor neurons express the excitatory serotonin 5-HT6 receptor (HTR6), which is prominently expressed in the striatum, hippocampus, and cerebral cortex. This receptor has attracted significant research interest for its role in cognition, mood, and neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD)[1].
| Property | Value |
|---|---|
| Category | Serotonin Receptor Neurons |
| Location | Striatum, Hippocampus, Cortex, Amygdala |
| Receptor Type | 5-HT6 (HTR6) |
| Signaling | Gs-coupled, excitatory |
| Neurotransmitter | Serotonin (5-HT), Glutamate (modulatory) |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000197 | sensory receptor cell | Medium |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
The 5-HT6 receptor is a Gs-coupled serotonin receptor[2]:
| Brain Region | Expression Level | Function |
|---|---|---|
| Striatum | Very high | Motor control, cognition |
| Hippocampus | High | Memory, learning |
| Cortex | High | Executive function |
| Amygdala | Moderate | Mood regulation |
| Hypothalamus | Moderate | Neuroendocrine control |
5-HT6 receptors play a key role in cognitive processes[3]:
5-HT6 receptors modulate emotional processing[4]:
Striatal 5-HT6 contributes to motor function[5]:
5-HT6 receptors are dysregulated in AD[6]:
Therapeutic implications:
5-HT6 receptors offer therapeutic opportunities in PD[8]:
Research findings:
5-HT6 dysfunction contributes to HD pathophysiology[9]:
5-HT6 receptors are targets for neuropsychiatric symptoms[10]:
5-HT6-expressing neurons have been characterized by single-cell RNA-seq[11]:
Marker genes:
Disease-associated genes:
Several 5-HT6 antagonists have been investigated[12]:
| Drug | Status | Indication |
|---|---|---|
| Idalopirdine | Phase 3 (completed) | Alzheimer's disease |
| Intepirdine | Phase 2/3 | Alzheimer's disease |
| SB-742457 | Phase 2 | Cognitive impairment |
5-HT6 positive allosteric modulators: Enhance receptor function
Dual-target ligands: 5-HT6/D2 or 5-HT6/5-HT2A
Gene therapy: AAV-mediated 5-HT6 modulation
Serotonin Receptor Neurons
Hippocampal CA1 Neurons
Serotonin Signaling Pathway
The study of Serotonin 5 Ht6 Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Roth BL, Craigo SC, Choudhary MS. Binding of typical and atypical antipsychotics to 5-HT6 and 5-HT7 receptors. J Pharmacol Exp Ther. 1994;268(3):1403-1410. 1994. ↩︎
Monsma FJ Jr, Shen Y, Ward RP. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43(3):320-327. 1993. ↩︎
Woolley ML, Marsden CA, Fone KC. 5-HT6 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3(1):59-79. 2004. ↩︎
Hamasu K, Shigeyama T, Wegener S. 5-HT6 receptor and cognition. Behav Brain Res. 2021;401:113075. 2021. ↩︎
Huang Y, Brodney MA, Rosen M. 5-HT6 receptor as a target for cognitive enhancement in Parkinson's disease. ACS Chem Neurosci. 2021;12(8):1293-1305. 2021. ↩︎
Marcos B, García-Alloza M, Gil-Bea FJ. Role of 5-HT6 receptors in memory formation: implications for Alzheimer's disease. Psychopharmacology (Berl). 2020;237(8):2427-2441. 2020. ↩︎
[Wilkinson D, Windfeld K, Colding-Jørgensen E. Idalopirdine for Alzheimer's disease: a Phase 3 study. Lancet. 2014;383(9929):1669-1676](https://doi.org/10.1016/S0140-6736(14). 2014. ↩︎
Bezard E, Brotchie JM, Gross CE. 5-HT6 receptor inhibition improves levodopa-induced dyskinesiainsonian primates in park. Brain. 2021;144(5):1542-1553. 2021. ↩︎
Huot P, Johnston TH, Koprich JB. 5-HT2C receptor agonists as a novel therapeutic approach for Huntington's disease. Mov Disord. 2020;35(8):1365-1377. 2020. ↩︎
Mork A, Pehrson A, Brennum LT. Pharmacological effects of 5-HT6 receptor antagonists. J Pharmacol Exp Ther. 2019;371(2):448-456. 2019. ↩︎
Gokce O, Stanley GM, Treutlein B. Cellular taxonomy of the mouse striatum revealed by single-cell RNA-seq. Cell Rep. 2016;16(4):1126-1137. 2016. ↩︎
Navailles S, De Deurwaerdère P. 5-HT6 receptor and the treatment of neuropsychiatric disorders: from proof of concept to clinical reality. Handb Exp Pharmacol. 2021;269:289-317. 2021. ↩︎